These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29216362)

  • 21. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
    Royer DJ; Gurung HR; Jinkins JK; Geltz JJ; Wu JL; Halford WP; Carr DJJ
    J Virol; 2016 Jun; 90(11):5514-5529. PubMed ID: 27030264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
    Awasthi S; Zumbrun EE; Si H; Wang F; Shaw CE; Cai M; Lubinski JM; Barrett SM; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
    J Virol; 2012 Apr; 86(8):4586-98. PubMed ID: 22318147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
    Awasthi S; Belshe RB; Friedman HM
    J Infect Dis; 2014 Aug; 210(4):571-5. PubMed ID: 24652496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD.
    Baghian A; Chouljenko VN; D'Auvergne O; Newman MJ; Baghian S; Kousoulas KG
    J Med Microbiol; 2002 Apr; 51(4):350-357. PubMed ID: 11926742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.
    Petro C; González PA; Cheshenko N; Jandl T; Khajoueinejad N; Bénard A; Sengupta M; Herold BC; Jacobs WR
    Elife; 2015 Mar; 4():. PubMed ID: 25756612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs.
    Odegard JM; Flynn PA; Campbell DJ; Robbins SH; Dong L; Wang K; Ter Meulen J; Cohen JI; Koelle DM
    Vaccine; 2016 Jan; 34(1):101-9. PubMed ID: 26571309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2.
    Mori I; Liu B; Goshima F; Ito H; Koide N; Yoshida T; Yokochi T; Kimura Y; Nishiyama Y
    Microbes Infect; 2005 Dec; 7(15):1492-500. PubMed ID: 16054416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of oral and parenteral routes for therapeutic vaccination with HSV-2 ISCOMs in mice; cytokine profiles, antibody responses and protection.
    Mohamedi SA; Heath AW; Jennings R
    Antiviral Res; 2001 Feb; 49(2):83-99. PubMed ID: 11248361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.
    Brans R; Yao F
    BMC Microbiol; 2010 Jun; 10():163. PubMed ID: 20525279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D.
    Whitbeck JC; Huang ZY; Cairns TM; Gallagher JR; Lou H; Ponce-de-Leon M; Belshe RB; Eisenberg RJ; Cohen GH
    J Virol; 2014 Jul; 88(14):7786-95. PubMed ID: 24789783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease.
    van Lint AL; Torres-Lopez E; Knipe DM
    Virology; 2007 Nov; 368(2):227-31. PubMed ID: 17915278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging.
    Cairns TM; Ditto NT; Lou H; Brooks BD; Atanasiu D; Eisenberg RJ; Cohen GH
    PLoS Pathog; 2017 Jun; 13(6):e1006430. PubMed ID: 28614387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses.
    Stanfield BA; Kousoulas KG; Fernandez A; Gershburg E
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
    Stanfield BA; Rider PJF; Caskey J; Del Piero F; Kousoulas KG
    Vaccine; 2018 May; 36(20):2842-2849. PubMed ID: 29655629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.
    Du R; Wang L; Xu H; Wang Z; Zhang T; Wang M; Ning Y; Deng F; Hu Z; Wang H; Li Y
    Antiviral Res; 2017 Nov; 147():131-141. PubMed ID: 29061442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
    Awasthi S; Shaw C; Friedman H
    Expert Rev Vaccines; 2014 Dec; 13(12):1475-88. PubMed ID: 25138572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
    Stanfield BA; Stahl J; Chouljenko VN; Subramanian R; Charles AS; Saied AA; Walker JD; Kousoulas KG
    PLoS One; 2014; 9(10):e109890. PubMed ID: 25350288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.